uniQure N.V.
Sector: Manufacturing
Industry: Pharmaceutical Products
13.15
0.36
(2.81%)
Volume:
1,766,406
52 week range:
3.73 - 19.18
Market Cap:
719.943M
Company Description:
uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.